OptimizeRx Co. (NASDAQ:OPRX) Receives Average Rating of “Moderate Buy” from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.06.

Several equities research analysts have issued reports on OPRX shares. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price target on shares of OptimizeRx in a report on Thursday, February 6th. Stephens assumed coverage on OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price objective on the stock. B. Riley upgraded shares of OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Lake Street Capital restated a “buy” rating and set a $11.00 price objective on shares of OptimizeRx in a research report on Tuesday, December 24th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $8.13 on Friday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm’s fifty day moving average price is $6.86 and its two-hundred day moving average price is $6.02. The firm has a market capitalization of $150.32 million, a P/E ratio of -6.11 and a beta of 1.18. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $14.13.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of the stock in a transaction dated Friday, March 14th. The stock was purchased at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the transaction, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. The trade was a 472.35 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds have recently added to or reduced their stakes in OPRX. BNP Paribas Financial Markets increased its position in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares in the last quarter. Rhumbline Advisers lifted its holdings in OptimizeRx by 10.5% during the first quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock worth $241,000 after acquiring an additional 2,636 shares during the period. Wells Fargo & Company MN raised its stake in shares of OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after purchasing an additional 2,797 shares during the period. Barclays PLC boosted its stake in OptimizeRx by 13.5% in the fourth quarter. Barclays PLC now owns 30,574 shares of the company’s stock valued at $148,000 after acquiring an additional 3,640 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new position in OptimizeRx in the first quarter valued at approximately $33,000. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.